We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Sets October User Fee Date for Avanir’s PBA Drug Zenvia
FDA Sets October User Fee Date for Avanir’s PBA Drug Zenvia
May 21, 2010
The FDA has received Avanir Pharmaceuticals’ complete response for Zenvia, its leading experimental compound for the treatment of the neurological disorder pseudobulbar affect (PBA).